Aurinia Drug Patent Portfolio
Aurinia owns 1 orange book drug protected by 3 US patents Given below is the list of Aurinia's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10286036 | Protocol for treatment of lupus nephritis | 07 Dec, 2037 | Active |
| US11622991 | Protocol for treatment of lupus nephritis | 07 Dec, 2037 | Active |
| US7332472 | Cyclosporine analogue mixtures and their use as immunomodulating agents | 17 Oct, 2025 | Active |
Latest Legal Activities on Aurinia's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aurinia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US7332472 |
| transaction for FDA Determination of Regulatory Review Period | 29 Nov, 2023 | US7332472 |
|
Interim Patent Term Extension Granted
Critical
| 02 Oct, 2023 | US7332472 |
| Post Issue Communication - Certificate of Correction | 27 May, 2023 | US11622991 |
|
Recordation of Patent Grant Mailed
Critical
| 11 Apr, 2023 | US11622991 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 11 Apr, 2023 | US11622991 |
|
Email Notification
Critical
| 23 Mar, 2023 | US11622991 |
|
Issue Notification Mailed
Critical
| 22 Mar, 2023 | US11622991 |
|
Email Notification
Critical
| 13 Mar, 2023 | US11622991 |
| Dispatch to FDC | 13 Mar, 2023 | US11622991 |
|
Application Is Considered Ready for Issue
Critical
| 13 Mar, 2023 | US11622991 |
| Mailing Corrected Notice of Allowability | 13 Mar, 2023 | US11622991 |
| Corrected Notice of Allowability | 07 Mar, 2023 | US11622991 |
|
Information Disclosure Statement considered
Critical
| 07 Mar, 2023 | US11622991 |
|
Pubs Case Remand to TC
Critical
| 27 Feb, 2023 | US11622991 |
Aurinia's Drug Patent Litigations
Aurinia's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Feb 24, 2022, against patent number US10286036. The petitioner Sun Pharmaceutical Industries Ltd. et al., challenged the validity of this patent, with Aurinia Pharmaceuticals Inc. as the respondent. Click below to track the latest information on how companies are challenging Aurinia's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US10286036 | February, 2022 |
Terminated-Settled
(25 Jan, 2023)
| Aurinia Pharmaceuticals Inc. | Sun Pharmaceutical Industries Ltd. et al. |
Aurinia's Family Patents
Aurinia Drug List
Given below is the complete list of Aurinia's drugs and the patents protecting them.
1. Lupkynis
Lupkynis is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10286036 | Protocol for treatment of lupus nephritis |
07 Dec, 2037
(13 years from now)
| Active |
| US11622991 | Protocol for treatment of lupus nephritis |
07 Dec, 2037
(13 years from now)
| Active |
| US7332472 | Cyclosporine analogue mixtures and their use as immunomodulating agents |
17 Oct, 2025
(11 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lupkynis's drug page